The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-22. Anything still debated is marked as such rather than presented as settled.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
== Products and services == Railway freight: Rolling stock, components (bogies, couplers, locomotive shells, gears); Railway transit: Rolling stock (electric locomotives, EMU trainsets, DEMU trainsets, metros, body shells, bogies, propulsion & electrical equipment); Automobile: Commercial electric vehicles, commercial vehicle load bodies; Containers: Marine container, refrigerated container, truck mounted container & cold chain transport container
India is a federal union comprising 28 states and 8 union territories. All states, as well as the union territories of Jammu and Kashmir, Puducherry and the National Capital Territory of Delhi, have elected legislatures and governments following the Westminster system. The remaining five union territories are directly ruled by the central government through appointed administrators. In 1956, under the States Reorganisation Act, states were reorganised on a linguistic basis. Over a quarter of a million local government bodies operate at the city, town, district, block, and village levels.
== Comparison with LASIK == Some theoretical advantages are that the technique is minimally invasive compared with LASIK and no collateral damage occurs to surrounding tissue due to the high speed of the femtosecond laser. There are limited studies on corneal wound healing and inflammatory response after this treatment has been carried out. There is a suggestion that the expression of fibronectin which is associated with wound healing is less in this method compared with femtosecond-LASIK. In some cases post operative tear secretion and dry eye syndrome have been observed along with similar post operative complications seen in LASIK surgery. Like PRK and LASEK, SMILE prevents the flap-related risks for example in contacts sports.
== Lawsuits == In November 2010, the parent company of Twin Peaks (Twin Restaurant IP LLC) accused Kevin Laughlin, the owner of Grand Tetons LLC DBA Northern Exposure, of trademark infringement. The lawsuit sought to prevent the opening of Northern Exposure's Fayetteville, Arkansas location after one of Twin Peaks' franchisee noticed a billboard similar to Twin Peaks but advertising Northern Exposure. The lawsuit was settled in the spring of 2011, with Laughlin paying Twin Peaks' legal fees related to the lawsuit. In July 2011, former Hooters executives including CEO and president Coby Brooks, CLO Clay Mingus, Joseph Hummel, Jim Tessmer, Roger Gondek, and the business administrator for the late Robert H. Brooks (founder of Hooters) Patti Frederick left Hooters and formed La Cima Restaurants LLC, a Twin Peaks franchisee. Hooters of America then filed suit against La Cima Restaurants and Joseph Hummel alleging Hummel had electronically sent "more than 500 pages" of Hooters' trade secrets to his private email weeks before he resigned. On May 1, 2012 the Atlanta Business Chronicle reported that Hooters had settled the lawsuit against La Cima and Hummel, with the terms that La Cima and Hummel return or destroy all stolen documents and not use any information on those documents in a competitive manner. On July 8, 2015, the widow of Jesus Delgado Rodriguez (one of the nine bikers killed in the 2015 Waco shootout) filed a lawsuit against Twin Peaks' parent company for negligence.
===== Interferon production ===== Because of powerful interferon stimulating properties, before recombinant interferon alpha became available for medical use, SeV was selected, among other viruses, for the industrial large-scale IFN production. A procedure involving inactivated SeV treatment of human peripheral blood leukocytes from donors' blood was used for this production. Below is a table that listed known PRRs and interferon regulatory factors that are getting activated upon SeV infection.
Sources: en.wikipedia.org
== Classification == A seroma contains serous fluid. This is composed of blood plasma that has seeped out of ruptured small blood vessels and the inflammatory fluid produced by injured and dying cells. Seromas are different from hematomas, which contain red blood cells, and abscesses, which contain pus and result from an infection. Serous fluid is also different from lymph.
== Industrial collaborations == Brenner is a former member of the Scientific Advisory Board of Sirtris Pharmaceuticals. He currently serves as chief scientific advisor of Niagen Bioscience and NADMED.
Somalia, officially the Federal Republic of Somalia, is the easternmost country in continental Africa. Stretching across the Horn of Africa, it borders Ethiopia to the west, Djibouti to the northwest, Kenya to the southwest, the Gulf of Aden to the north, and the Indian Ocean to the east. Somalia has the longest coastline on Africa's mainland. Somalia has an estimated population over 19 million, of which 2.7 million live in the capital and largest city, Mogadishu. As one of Africa's most ethnically homogeneous countries, around 85% of its residents are ethnic Somalis. The official and national language of the country is Somali, and Arabic is recognised as a second language. The overwhelming majority of the population are Sunni Muslims. In ancient history, Somalia was an important commercial centre. During the Middle Ages, several powerful Somali empires dominated the regional trade, including the Ajuran Sultanate, Adal Sultanate, and the Sultanate of the Geledi. In the late 19th century, the Somali sultanates were colonised by the Italian and British empires, who merged these tribal territories into two colonies: Italian Somaliland and British Somaliland. In 1960, the two territories united to form the independent Somali Republic under a civilian government. Siad Barre of the Supreme Revolutionary Council (SRC) seized power in 1969 and established the Somali Democratic Republic, launching a failed invasion of Ethiopia which triggered major instability in Somalia and brutally attempting to quash the Somaliland War of Independence in the north of the country.
According to the marketeer, the old name "McDonald's" will soon disappear from the lexicon of the Russian consumers, and, to not pronounce the long phrase, clients of the chain will make up their own. On 13 June, various messages appeared claiming that the logo of Vkusno i tochka is a lazy alteration of a Portuguese pet food brand "Matosmix". On 15 June, the director of a fast food chain known as "Food, full stop" (Russian: Еда и точка) in Primorsky Krai, Sergei Ponkratov, accused the new chain of plagiarism and decided to sue it, demanding a change of the name. He claims that the Vkusno i tochka brand clearly intersects with and deprives his trademark, which has been operating since 2018, of uniqueness and recognizability.
=== Affinity-based Screening === Screening is used to find the apparent affinities of heterologous proteins displayed on the bacterial cell surface for target proteins. This method is usually combined with FACS, and the addition of a non-fluorescent target protein competitor is beneficial to obtaining more accurate binding affinities. Adding a competitor reduces the chance of target proteins rebinding, which would render the binding affinity less accurate.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.